Table 1.
General characteristics of the study population.
| RANSM with IBR (n = 12) | |
|---|---|
| Age (years) | 46 (29–51) |
| BMI (kg/m2) | 20.8 (18.59–23.93) |
| Breast weight (g) | 225.5 (150–436) |
| Diagnosis | |
| Benign | 2 (16.7) |
| DCIS | 1 (8.3) |
| IDC | 9 (75) |
| Tumor size (cm) (n = 10)* | 2.3 (0.5–4.2) |
| No. of metastatic lymph nodes (n = 10)* | |
| 0 | 8 (80) |
| 1 | 2 (20) |
| Histopathological grade (n = 10)* | |
| 1 | 0 (0) |
| 2 | 6 (60) |
| 3 | 4 (40) |
| Estrogen receptor status (n = 10)* | |
| Negative | 0 (0) |
| Positive | 10 (100) |
| Progesterone receptor status (n = 10)* | |
| Negative | 1 (10) |
| Positive | 9 (90) |
| HER2 status (n = 10)* | |
| Negative | 7 (70) |
| Positive | 3 (30) |
| Ki 67 (n = 10)* | |
| Low (<14%) | 5 (50) |
| High (≥14%) | 5 (50) |
| Adjuvant chemotherapy (n = 10)* | |
| No | 6 (60) |
| Yes | 4 (40) |
| Radiotherapy (n = 10)* | |
| No | 8 (80) |
| Yes | 2 (20) |
| Hormonal therapy (n = 10)* | |
| No | 0 (0) |
| Yes | 10 (100) |
| Targeted therapy (n = 10)* | |
| No | 9 (90) |
| Yes | 1 (10) |
Values are represented as median (minimum–maximum) or N (percentage).
*2 cases showed a benign presentation.
BMI: body mass index, DCIS: ductal carcinoma in situ, HER: human epidermal growth factor receptor, IBR: immediate breast reconstruction, IDC: invasive ductal carcinoma, RANSM: robot-assisted nipple-sparing mastectomy.